Contributed by Alison Kawai, ScD, Senior Research Epidemiologist, RTI Health Solutions
Skeletal related events (SRE) are common in men with bone metastases and have negative consequences for men with castration resistant prostate cancer (CRPC), including pain, reduced quality of life, and increased risk of death. However, no study has assessed incidence rates of these events from the time of castration resistance.
Research to fill this gap that several colleagues and I coauthored was recently published in Prostate Cancer and featured in Renal and Urology News. The study utilized SEER-Medicare, a large database of Medicare enrollees with linked claims and cancer registry data, to estimate the incidence of SREs in men with CRPC.
We found that SREs were quite common in this population–with a cumulative incidence of 40% during a mean follow-up of 10.6 months. The incidence rate of first SRE was higher in white men than in black men, possibly due to higher bone density in black men. The incidence rate of first SREs before use of bone targeted agents appeared to be higher than after use of bone targeted agents (4.16 vs. 3.60 per 100 person months), though the magnitude of the effect of bone targeted agents may have been overestimated due to confounding by indication or other factors not addressable in claims data.
These findings could serve as the basis for other real-world studies on the incidence of SREs and therapeutic strategies in men with CRPC.
Read the abstract here.